Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer

Inclusion Criteria

• •Patients who have been histopathologically diagnosed with colorectal adenocarcinoma;
• •Patients who have undergone radical curative resection of the primary tumors;
• •Patients with CRC of high-risk stage II and stage III based on final findings (UICC TNM Classification, 8th Edition);
• •Patients who tested positive for ctDNA methylation at 5-7 days after surgery prior to enrollment;
• •Patients with no obvious relapse confirmed by chest, abdominal, and pelvic CT scans, etc.;
• •Patients aged ≥ 18 and ≤80 years old, regardless of gender;
• •Patients with expected survival of more than 12 months;
• •Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;
• •Patients who have no severe disorder in major organs (such as the bone marrow, heart, lungs, liver, and kidneys) and meet the following criteria: Neutrophil count ≥ 1,500/mm3, Platelet count ≥ 100,000/mm3, Hemoglobin ≥ 8.0 g/dL, Serum creatinine ≤ 1.5 mg/dL, Total bilirubin ≤ 1.5 mg/dL, ALT and AST ≤ 100 U/L
• •Patients with no diarrhea or stomatitis of Grade 2 or severer according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0;
• •Patients who voluntarily gave written consent to participate in the trial after receiving a thorough explanation of the trial before enrolling in the trial